Article(id=1322181147178680883, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322181102488375822, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1598630400000, acceptedDateStr=2020-08-29, onlineDate=1793162150424, onlineDateStr=2026-10-28, pubDate=1627574400000, pubDateStr=2021-07-30, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793162150424, onlineIssueDateStr=2026-10-28, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793162150424, creator=13701087609, updateTime=1793162150424, updator=13701087609, issue=Issue{id=1322181102488375822, tenantId=1146029695717560320, journalId=1235980733773295621, year='2021', volume='30', issue='14', pageStart='1249', pageEnd='1344', issueExtLink='null', onlineDate='null', pubDate='1627574400000', pubDateStr='2021-07-30', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=0, createTime=1793162139770, creator='13701087609', updateTime=1793162209831, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322181396408419308, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322181102488375822, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322181396408419309, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322181102488375822, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1249, endPage=1254, ext={EN=ArticleExt(id=1322181148931899956, articleId=1322181147178680883, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=Exclusionary barriers of generic drugs replacing innovative drugs and american breakthrough in practice, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Innovative drug companies can obtain patent rights and exclusive rights for drug trial data for new drugs, their initial uses and new uses developed in the future. Both rights are exclusive rights, which are designed to protect innovative drug companies in their predominant position in the market. The initial exclusivity and subsequent exclusivity of innovative drugs constitute institutional barriers to the marketing of generic drugs. However, in the practice of the United States, once the initial exclusivity expires, generic drugs will be encouraged to enter the market. Actually, subsequent exclusivity cannot prevent the process of the replacement of innovative drugs by generic drugs. This article analyzes the practical measures of American society to break through institutional barriers from three aspects of administrative supervision, medical practice and judicial relief, and finds that the evasion of subsequent exclusive rights by stakeholders in administrative supervision. Furthermore, medical practice is the main reason for the breakthrough of institutional barriers. The difficulty of asserting the subsequent exclusivity is the secondary reason for the breakthrough of institutional barriers.

, authors=Chun-yang JIN, authorsList=Chun-yang JIN, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322181149674291765, articleId=1322181147178680883, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=仿制药替换创新药的排他权壁垒与美国实践突破研究, columnId=1236331162679955859, journalTitle=中国新药杂志, columnName=新药述评与论坛, runingTitle=null, highlight=null, articleAbstract=

创新药公司对于新药、其初始用途以及后续研发出的新用途都可取得专利权及药物试验数据专有权保护,这2种权利皆为排他权,旨在保障创新药公司在市场上拥有独占性营销地位。创新药的初始排他权和后续排他权构成仿制药上市的制度壁垒。但在美国的实践中,一旦初始排他权到期,仿制药将被鼓励上市,后续排他权实际上无法阻止仿制药替换创新药的进程。本研究从行政监管、医药实践及司法救济3个方面,解析美国社会突破制度壁垒的实践举措,发现利益相关方在行政监管和医药实践中规避后续排他权是制度壁垒得以突破的主要原因,而后续排他权本身侵权易、维权难的特点是制度壁垒得以突破的次要原因。

, authors=金春阳, authorsList=金春阳, authorCompany=null, correspAuthors=null, authorNote=

金春阳,男,教授,博士,主要从事知识产权法研究。E-mail:。

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=SzgffEsi2rwi7KUVKi1QEA==, magXml=Ak2Fl8+RYozNTNFwu4I9bA==, pdfUrl=null, pdf=ZQe4EPeYgq+GsAbPUxEPow==, pdfFileSize=1521744, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=V3xnMa/036ZOPCKpfh4ZHg==, mapNumber=null, fund=null)}, authors=[Author(id=1322181150081139258, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=1912967135@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322181150173413948, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, authorId=1322181150081139258, language=EN, stringName=Chun-yang JIN, firstName=Chun-yang, middleName=null, lastName=JIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=School of Law, Xi'an Jiaotong University, Xi'an 710049, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322181150261494333, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, authorId=1322181150081139258, language=CN, stringName=金春阳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=西安交通大学法学院,西安 710049, bio={"content":"

金春阳,男,教授,博士,主要从事知识产权法研究。E-mail:。

"}, bioImg=null, bioContent=

金春阳,男,教授,博士,主要从事知识产权法研究。E-mail:。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322181149934338614, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, xref=null, ext=[AuthorCompanyExt(id=1322181149946921527, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, companyId=1322181149934338614, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Law, Xi'an Jiaotong University, Xi'an 710049, China), AuthorCompanyExt(id=1322181149967893048, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, companyId=1322181149934338614, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=西安交通大学法学院,西安 710049)])])], keywords=[Keyword(id=1322181150412489278, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=EN, orderNo=1, keyword=method patent), Keyword(id=1322181150492181055, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=EN, orderNo=2, keyword=drug patent), Keyword(id=1322181150584455744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=EN, orderNo=3, keyword=patent linkage), Keyword(id=1322181150659953217, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=EN, orderNo=4, keyword=innovative drug), Keyword(id=1322181150764810818, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=EN, orderNo=5, keyword=generic drug), Keyword(id=1322181150861279811, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=CN, orderNo=1, keyword=方法专利), Keyword(id=1322181150961943108, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=CN, orderNo=2, keyword=药品专利), Keyword(id=1322181151041634885, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=CN, orderNo=3, keyword=专利链接), Keyword(id=1322181151117132358, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=CN, orderNo=4, keyword=创新药), Keyword(id=1322181151205212743, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, language=CN, orderNo=5, keyword=仿制药)], refs=[Reference(id=1322181153142981194, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=DOLIN G. Exclusivity without patents: the new frontier of FDA regulation for genetic materials[J]. Iowa Law Rev, 2013, 98(4): 1399-1423., articleTitle=null, refAbstract=null), Reference(id=1322181153239450187, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=LIETZAN E. The uncharted waters of competition and innovation in biological medicines[J]. Florida Sta Uni Law Rev, 2017, 44(3): 883-937., articleTitle=null, refAbstract=null), Reference(id=1322181153436582476, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Caraco Pharm. Labs. V. Novo Nordisk A/S, 566 U.S. 399 (2012) (No.10-844)[S]. 2011., articleTitle=null, refAbstract=null), Reference(id=1322181153541440077, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=GRABOWSKI HG, MOE JL. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention[J]. Cancer Prev Res, 2008, 1(2): 84-90., articleTitle=null, refAbstract=null), Reference(id=1322181153629520462, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Bristol-Myers Squibb Co. V. Shalala, 91 F. 3d 1493, 1499[S]. 1996., articleTitle=null, refAbstract=null), Reference(id=1322181153734378063, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Bristol-Myers Squibb Co. V. Shalala, 91 F. 3d 1493, 1500[S]. 1996., articleTitle=null, refAbstract=null), Reference(id=1322181153822458448, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Sigma-Tau Pharm. Inc. V. Schwetz, 288 F. 3d 141, 147-148[S]. 2002., articleTitle=null, refAbstract=null), Reference(id=1322181153902150225, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=GRABOWSKI HG, VERNON JM. Substitution laws and innovation in the pharmaceutical industry[J]. Law Contemp Prob, 1979, 43: 49-60., articleTitle=null, refAbstract=null), Reference(id=1322181153973453394, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=New York ex rel. Schneiderman v. Actavis PLC, 787 F. 3d 638, 644-645[S]. 2015., articleTitle=null, refAbstract=null), Reference(id=1322181154048950867, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=ZETTLER PJ. Toward coherent federal oversight of medicine[J]. San Diego Law Rev, 2015, 52: 427-437., articleTitle=null, refAbstract=null), Reference(id=1322181154145419860, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=JOHNSON SH. Polluting medical judgment? false assumptions in the pursuit of false claims regarding off label prescribing[J]. Minn J Law, Sci Technol, 2008, 9: 61-68., articleTitle=null, refAbstract=null), Reference(id=1322181154262860373, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=STAFFORD RS. Regulating off-label drug use: rethinking the role of the FDA[J]. N Engl J Med, 2008, 358: 1427-1437., articleTitle=null, refAbstract=null), Reference(id=1322181154334163542, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=姚立新, 郑强. 制药创新激励不足的原因与FDA的采取的对策[J]. 中国新药杂志, 2019, 28(9): 1025-1036., articleTitle=null, refAbstract=null), Reference(id=1322181154418049623, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Takeda Pharm. U.S.A., Inc. v. West-Ward Pharm. Corp., 785 F. 3d 625, 630-631[S]. 2015., articleTitle=null, refAbstract=null), Reference(id=1322181154497741400, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Warner-Lambert Co. v. Apotex Corp., 316 F. 3d 1348, 1364[S]. 2003., articleTitle=null, refAbstract=null)], funds=[Fund(id=1322181151343624776, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, awardId=留金美[2020]1509, language=CN, fundingSource=2020年教育部项目(留金美[2020]1509), fundOrder=null, country=null), Fund(id=1322181151431705161, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, awardId=null, language=CN, fundingSource=西安交通大学2020年课程思政专项研究重点项目, fundOrder=null, country=null)], companyList=[AuthorCompany(id=1322181149934338614, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, xref=null, ext=[AuthorCompanyExt(id=1322181149946921527, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, companyId=1322181149934338614, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Law, Xi'an Jiaotong University, Xi'an 710049, China), AuthorCompanyExt(id=1322181149967893048, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, companyId=1322181149934338614, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=西安交通大学法学院,西安 710049)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1788948968376, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509780974924039, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968404, updatedTime=1788948968404, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509781025255688, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968416, updatedTime=1788948968416, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2021/V30/I14/1249, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2021/V30/I14/1249, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2021/V30/I14/1249, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2021/V30/I14/1249, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1627574400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
仿制药替换创新药的排他权壁垒与美国实践突破研究
收藏切换
PDF下载
金春阳
中国新药杂志 | 新药述评与论坛 2021,30(14): 1249-1254
收起
收藏切换
中国新药杂志 |新药述评与论坛 2021 , 30 (14) : 1249 -1254
仿制药替换创新药的排他权壁垒与美国实践突破研究
全屏
[Author(id=1322181150081139258, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=1912967135@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322181150173413948, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, authorId=1322181150081139258, language=EN, stringName=Chun-yang JIN, firstName=Chun-yang, middleName=null, lastName=JIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=School of Law, Xi'an Jiaotong University, Xi'an 710049, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322181150261494333, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, authorId=1322181150081139258, language=CN, stringName=金春阳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=西安交通大学法学院,西安 710049, bio={"content":"

金春阳,男,教授,博士,主要从事知识产权法研究。E-mail:。

"}, bioImg=null, bioContent=

金春阳,男,教授,博士,主要从事知识产权法研究。E-mail:。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322181149934338614, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, xref=null, ext=[AuthorCompanyExt(id=1322181149946921527, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, companyId=1322181149934338614, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=School of Law, Xi'an Jiaotong University, Xi'an 710049, China), AuthorCompanyExt(id=1322181149967893048, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181147178680883, companyId=1322181149934338614, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=西安交通大学法学院,西安 710049)])])]
金春阳
作者信息
  • 西安交通大学法学院,西安 710049
作者简介:

金春阳,男,教授,博士,主要从事知识产权法研究。E-mail:。

Exclusionary barriers of generic drugs replacing innovative drugs and american breakthrough in practice
Chun-yang JIN
Affiliations
  • School of Law, Xi'an Jiaotong University, Xi'an 710049, China
出版时间: 2021-07-30
文章导航
收藏切换

创新药公司对于新药、其初始用途以及后续研发出的新用途都可取得专利权及药物试验数据专有权保护,这2种权利皆为排他权,旨在保障创新药公司在市场上拥有独占性营销地位。创新药的初始排他权和后续排他权构成仿制药上市的制度壁垒。但在美国的实践中,一旦初始排他权到期,仿制药将被鼓励上市,后续排他权实际上无法阻止仿制药替换创新药的进程。本研究从行政监管、医药实践及司法救济3个方面,解析美国社会突破制度壁垒的实践举措,发现利益相关方在行政监管和医药实践中规避后续排他权是制度壁垒得以突破的主要原因,而后续排他权本身侵权易、维权难的特点是制度壁垒得以突破的次要原因。

方法专利  /  药品专利  /  专利链接  /  创新药  /  仿制药

Innovative drug companies can obtain patent rights and exclusive rights for drug trial data for new drugs, their initial uses and new uses developed in the future. Both rights are exclusive rights, which are designed to protect innovative drug companies in their predominant position in the market. The initial exclusivity and subsequent exclusivity of innovative drugs constitute institutional barriers to the marketing of generic drugs. However, in the practice of the United States, once the initial exclusivity expires, generic drugs will be encouraged to enter the market. Actually, subsequent exclusivity cannot prevent the process of the replacement of innovative drugs by generic drugs. This article analyzes the practical measures of American society to break through institutional barriers from three aspects of administrative supervision, medical practice and judicial relief, and finds that the evasion of subsequent exclusive rights by stakeholders in administrative supervision. Furthermore, medical practice is the main reason for the breakthrough of institutional barriers. The difficulty of asserting the subsequent exclusivity is the secondary reason for the breakthrough of institutional barriers.

method patent  /  drug patent  /  patent linkage  /  innovative drug  /  generic drug
金春阳. 仿制药替换创新药的排他权壁垒与美国实践突破研究. 中国新药杂志, 2021 , 30 (14) : 1249 -1254 .
Chun-yang JIN. Exclusionary barriers of generic drugs replacing innovative drugs and american breakthrough in practice[J]. Chinese Journal of New Drugs, 2021 , 30 (14) : 1249 -1254 .
  • 2020年教育部项目(留金美[2020]1509)
  • 西安交通大学2020年课程思政专项研究重点项目
参考文献 引证文献
排序方式:
[1]
DOLIN G. Exclusivity without patents: the new frontier of FDA regulation for genetic materials[J]. Iowa Law Rev, 2013, 98(4): 1399-1423.
[2]
LIETZAN E. The uncharted waters of competition and innovation in biological medicines[J]. Florida Sta Uni Law Rev, 2017, 44(3): 883-937.
[3]
Caraco Pharm. Labs. V. Novo Nordisk A/S, 566 U.S. 399 (2012) (No.10-844)[S]. 2011.
[4]
GRABOWSKI HG, MOE JL. Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention[J]. Cancer Prev Res, 2008, 1(2): 84-90.
[5]
Bristol-Myers Squibb Co. V. Shalala, 91 F. 3d 1493, 1499[S]. 1996.
[6]
Bristol-Myers Squibb Co. V. Shalala, 91 F. 3d 1493, 1500[S]. 1996.
[7]
Sigma-Tau Pharm. Inc. V. Schwetz, 288 F. 3d 141, 147-148[S]. 2002.
[8]
GRABOWSKI HG, VERNON JM. Substitution laws and innovation in the pharmaceutical industry[J]. Law Contemp Prob, 1979, 43: 49-60.
[9]
New York ex rel. Schneiderman v. Actavis PLC, 787 F. 3d 638, 644-645[S]. 2015.
[10]
ZETTLER PJ. Toward coherent federal oversight of medicine[J]. San Diego Law Rev, 2015, 52: 427-437.
[11]
JOHNSON SH. Polluting medical judgment? false assumptions in the pursuit of false claims regarding off label prescribing[J]. Minn J Law, Sci Technol, 2008, 9: 61-68.
[12]
STAFFORD RS. Regulating off-label drug use: rethinking the role of the FDA[J]. N Engl J Med, 2008, 358: 1427-1437.
[13]
姚立新, 郑强. 制药创新激励不足的原因与FDA的采取的对策[J]. 中国新药杂志, 2019, 28(9): 1025-1036.
[14]
Takeda Pharm. U.S.A., Inc. v. West-Ward Pharm. Corp., 785 F. 3d 625, 630-631[S]. 2015.
[15]
Warner-Lambert Co. v. Apotex Corp., 316 F. 3d 1348, 1364[S]. 2003.
2021年第30卷第14期
PDF下载
12
1
引用本文
BibTeX
文章信息
  • 首发时间:2026-10-28
  • 出版时间:2021-07-30
补充材料
相关文章
文章信息
作者
出版历史
  • 录用日期:2020-08-29
基金
2020年教育部项目(留金美[2020]1509)
西安交通大学2020年课程思政专项研究重点项目
作者信息
    西安交通大学法学院,西安 710049
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322181147178680883
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏